What were the key takeaways from Roivant Sciences’s earnings call?

What does Roivant Sciences do and what are its main business segments?

Did Roivant Sciences beat or miss consensus estimates last quarter?

What is Roivant Sciences's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Roivant Sciences year over year?

What factors drove the changes in Roivant Sciences's revenue and profit?

What guidance did Roivant Sciences's management provide for the next earnings period?

What is Roivant Sciences's gross profit margin?

- **Breakthrough Sarcoidosis Data**: Brepocitinib achieved 21.6-point CSAMI improvement, 100% high-dose responders, and no safety surprises in Phase II.
- **Pipeline Momentum**: 9+ pivotal studies readouts in 2026, including PH-ILD, D2T RA, and Graves' disease.
- **Financial Strength**: $4.5B cash, no near-term capital needs despite ~$300M annual R&D spend.
- **Strategic Focus**: Orphan inflammation leadership with brepocitinib (3 Phase III programs) and FcRn franchise (IMVT-1402).

**【CEO & COO Presentation Summary】**
- **Phase II Success for Brepocitinib in Cutaneous Sarcoidosis**: Showed a 21.6-point improvement in CSAMI score (p < 0.001) vs. placebo, with 100% of high-dose patients achieving ≥10-point improvement. Safety profile consistent with prior studies.
- **Pipeline Momentum**: 
  - Phase III for brepocitinib in cutaneous sarcoidosis to start in 2026.
  - Phase IIb D2T RA study fully enrolled (170 patients vs. 120 target).
  - Mosapride (PH-ILD) Phase II fully enrolled; data expected H2 2026.
  - IMVT-1402 (Graves' disease) pivotal data expected 2027.
- **Financial Update**: 
  - Q3 2025 R&D expenses: $165M (non-GAAP $147M).
  - G&A expenses: $175M (non-GAAP $71M).
  - Cash balance: $4.5B, supporting multiple late-stage programs.

**【Q&A Highlights】**
- **Pricing Strategy**: Orphan drug pricing envelope similar to IVIG ($180-870/Mo), with final decision pending Phase III data.
- **Phase III Design**: Likely similar to DM trial (~300-400 patients), leveraging 1,500+ patient safety database. 45mg dose preferred based on efficacy/safety balance.
- **Competitive Landscape**: PH-ILD has no approved therapies; mosapride's PVR reduction profile could offer best-in-class potential.
- **Moderna Trial**: Jury trial set for March 9; favorable Section 1498 ruling preserves ~90% of asserted doses for damages calculation.
- **Commercial Synergy**: Separate field forces for brepocitinib and 1402, with shared contracting and patient engagement strategies.

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

- **Breakthrough DM Therapy**: Brepocitinib Phase III data shows 100% primary endpoint success; first novel oral DM therapy NDA submission on track for H1 2026.
- **Graves' Disease Innovation**: Batoclimab delivers 75% off ATDs in remission; durable IgG reductions suggest FcRn leadership in autoimmune diseases.
- **Litigation Strength**: $4.4B cash buffer supports pipeline despite LNP litigation risks; Moderna trial set for March 2026 with limited damages exposure.
- **Pipeline Expansion**: 11 registrational trials across FcRn (Sjögren's, RA) and LNP (NIU) programs; Investor Day to detail commercialization strategy.

**【CEO Summary Section】**
- **Brepocitinib Phase III Success**: Achieved statistical significance across all primary and secondary endpoints in dermatomyositis (DM), with 30mg dose showing rapid and broad clinical responses. NDA submission for DM expected in H1 2026.
- **Graves' Disease Remission Data**: Batoclimab (IMVT-1402) demonstrated durable remission in 17/21 patients off therapy for 6 months, with 75% off or on low-dose ATDs. Phase III trials in Graves', myasthenia gravis, and CIDP are ongoing.
- **Litigation Update**: Favorable Markman ruling in Genevant v. Pfizer; Moderna trial scheduled for March 2026. Global cash position remains strong at $4.4B.
- **Pipeline Expansion**: 11 registrational trials across FcRn therapies (e.g., Sjögren's, RA) and LNP-related programs. Investor Day on Dec 11 to detail commercial strategy.

**【CFO Financial Commentary】**
- **Financial Health**: Loss from continuing operations of $166M; no debt; $4.4B cash reserves supporting pipeline through profitability.
- **Shareholder Returns**: $500M buyback program active; share count reduced by 18% over 18 months.

**【Q&A Key Highlights】**
- **Competitive Landscape**: Argenx's VYVGART expected to launch in Graves' post-2026; Roivant's FcRn mechanism (deeper IgG reduction) positions for best-in-class. Sjögren's data from Novartis underscores market opportunity for FcRn differentiation.
- **LNP Litigation**: Moderna U.S. sales <50% of global; 1498 Act damages <$5B. International trials in UPC, Canada, Japan progressing; potential 2026 decisions.
- **Business Development**: Focus on high-value FcRn indications (e.g., RA, CLE); pipeline expansion via BD opportunities for large-market assets.

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

- **Brepocitinib DM data imminent**: 98% of patients achieved steroid taper, with 40% off steroids; NDA filing guidance for early 2026.
- **Grave's disease innovation**: Testing 300mg dose to establish minimally efficacious profile; 6-month remission data at ATA could transform treatment paradigm.
- **Litigation progress**: U.S. trial vs. Moderna set for March 2026; $4.5B cash war chest supports aggressive pipeline expansion.
- **Shareholder returns**: 15% share count reduction via buyback; $500M authorized for future opportunistic repurchases.

**【CEO Summary Section】**
- **Three key themes for 2025**: Progress with IMVT-1402 (anti-FcRn antibody), upcoming registrational data for brepocitinib in dermatomyositis (DM), and ongoing LNP litigation with Moderna and Pfizer.
- **Pipeline updates**: Brepocitinib has 5 registrational trials ongoing, including DM and non-infectious uveitis. IMVT-1402 is advancing in Grave's disease with a Phase II trial showing 6-month remission data to be presented at ATA in September.
- **Share repurchase program**: Completed $1.5 billion buyback (150M shares at $10 avg), reducing share count by 15%. Authorized additional $500M for opportunistic use.

**【CFO Financial Commentary】**
- Q1 2025: Adjusted net loss of $170M, cash utilization of $200M, and $4.5B cash balance (no debt).
- **Financial strength**: Strong liquidity to support pipeline expansion and upcoming catalysts.

**【Q&A Key Highlights】**
- **Brepocitinib DM trial**: 98% of patients achieved steroid taper (40% off steroids entirely), with data expected in late 2025. FDA filing guidance for NDA submission in early 2026.
- **Grave's disease strategy**: Testing lower 300mg dose to establish minimally efficacious dose for FDA approval. 6-month remission data at ATA could drive enrollment in registrational trial.
- **LNP litigation**: U.S. trial vs. Moderna scheduled for March 2026; summary judgment motions filed on patent validity and liability. International hearings expected in H1 2026.
- **Business development**: Actively pursuing late-stage autoimmune assets, particularly in China, with focus on FcRn and JAK1/2 mechanisms.

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

- **Pipeline Momentum**: Brepocitinib pivotal trials in DM and NIU; IMVT-1402 shows ~80% IgG suppression across autoimmune diseases.
- **Litigation Risk**: Moderna trial nearing resolution; Pfizer case Markman ruling pending.
- **Financial Strength**: $5B cash, 15% share reduction; $2B reserved for M&A.
- **DM Commercial Potential**: 30-70K U.S. patients, oral JAK inhibitor vs. IVIg off-label use.

**【CEO Overview】**
- **Revenue Growth**: FY2025 revenue driven by recovery in North American market, with a focus on AI investment and gross margin improvement in H2.
- **Pipeline Highlights**: Brepocitinib targeting DM and NIU with pivotal trials expected in H2; IMVT-1402 (anti-FcRn) showing deep IgG suppression (~80%) across Graves’ disease, MG, and CIDP.
- **Litigation Update**: LNP litigation with Moderna in summary judgment phase, trial expected soon; Pfizer case awaiting Markman ruling.

**【CFO Financial Update】**
- **Cash Position**: ~$5B cash on hand, $1.3B shares repurchased (15% reduction), with $2B reserved for BD opportunities.
- **Cost Management**: Strong operating expense control, supporting capital allocation for R&D and shareholder returns.

**【Q&A Key Takeaways】**
- **DM Study Design**: TIS endpoint with mandatory steroid taper; placebo response informed by historical data (~30-35 TIS improvement). Commercial focus on oral JAK inhibitor vs. IVIg.
- **1402 in Graves**: 26-52 week studies measuring clinical remission and proptosis progression; potential chronic therapy opportunity.
- **Competitive Pricing**: Flexible pricing strategy for orphan vs. prevalent indications, leveraging FcRn’s IgG lowering profile.

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

- **2025 Pivotal Year**: Multiple readouts including MG/CIDP (Q2), DM (Q4), and LNP litigation (Q4).
- **Pipeline Expansion**: Brepocitinib adds CS indication; batoclimab Graves' 6-month remission data expected summer 2025.
- **Financial Fortitude**: $5.2B cash, $1B+ buybacks, no debt - enabling multi-front clinical execution.
- **Key Risks**: LNP litigation outcome uncertainty; MG data market reaction sensitivity.
- **Differentiation**: Subcutaneous auto-injector and IgG suppression depth set Immunovant apart.


**【CEO Opening Remarks】**
- **2025 Strategic Milestones**: Highlighted key upcoming events including MG/CIDP data readouts, dermatomyositis (DM) registrational trial, and LNP litigation against Moderna/Pfizer-BioNTech. 
- **Pipeline Strength**: Emphasized brepocitinib's potential as a multi-indication franchise with $5.2B cash balance and $1B+ stock buybacks.
- **New Indication Launch**: Announced cutaneous sarcoidosis (CS) trial for brepocitinib, targeting 30k-50k patients with no approved therapies.

**【Pipeline Updates】**
- **Immunovant (Anti-FcRn Franchise)**:
  - Batoclimab Phase 3 MG/CIDP data expected Q2 2025; aiming for 80% IgG suppression via subcutaneous auto-injector.
  - Graves' disease Phase 2b results show 65% response rate; 6-month remission data expected summer 2025.
  - 6 INDs cleared for rare autoimmune diseases, with 4 trials launching by Q1 2026.
- **Brepocitinib Expansion**:
  - DM registrational trial on track for 2025 readout; exploring PH-ILD and NIU indications.
  - CS trial (BEACON) with 3:3:2 randomization targeting 16-week efficacy vs. placebo.

**【Litigation & Financials】**
- **LNP Litigation**: Moderna trial summary judgment phase Q2-Q3 2025; jury trial scheduled for Q4 2025.
- **Financial Position**: $5.2B cash post-Dermavant sale; $1B+ stock buybacks completed. No debt outstanding.
- **R&D/G&A**: Q3 2024 expenses $142M (R&D) / $71M (G&A), reflecting disciplined spending on late-stage assets.

**【Q&A Highlights】**
- **MG Data Bar**: CEO emphasized form factor (auto-injector) and dosing regimen differentiation over efficacy delta.
- **CS Trial Design**: Proof-of-concept study powered for signal detection, not statistical significance.
- **LNP Litigation Risk**: DOJ statement suggests limited 1498 defense applicability; outcome range from full liability to partial damages allocation.
- **Immunovant Investment**: Strategic buy-in to maintain control while preserving Roivant capital flexibility.


Actual	-0.32	-0.41	-0.2711	-0.48	-0.2927	-0.4135	-0.2189	-0.2267	-0.2627	6.03	-0.19	0.12	-0.31	0.23	-0.29	-0.2518	-0.2019	-0.17
Forecast	-0.3251	-0.2546	-0.3059	-0.3196	-0.3788	-0.3945	-0.3614	-0.2833	-0.288	-0.309	-0.2644	-0.2433	-0.247	-0.2529	-0.2635	-0.2497	-0.3198	-0.2995
Surprise	+1.57%	-61.04%	+11.38%	-50.19%	+22.73%	-4.82%	+39.43%	+19.98%	+8.78%	+2051.46%	+28.14%	+149.32%	-25.51%	+190.95%	-10.06%	-0.84%	+36.87%	+43.24%

ROIV

ROIV fundamentals

ROIV Q3 2026 Earnings

Earnings Call

You can ask Aime

ROIV

ROIV fundamentals

ROIV Q3 2026 Earnings

Earnings Call

ROIV Earnings Call Summary for Q3/20268:00 AM on Feb 6, 2026

ROIV Earnings Call Summary for Q2/20268:00 AM on Nov 10, 2025

ROIV Earnings Call Summary for Q1/20268:00 AM on Aug 11, 2025

ROIV Earnings Call Summary for Q4/20258:00 AM on May 29, 2025

ROIV Earnings Call Summary for Q3/20258:00 AM on Feb 10, 2025

You can ask Aime